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Key updates
An increasing trend in the health burden of CSLD and 
bronchiectasis is recognised in both Indigenous and 
non-Indigenous settings in Australia, New Zealand and 
worldwide.3,5-7 Some affluent countries report childhood 
fatalities,7 and there is a growing appreciation of the eco-
nomic cost.5 Misdiagnosis or coexistence of bronchiectasis 
with other chronic respiratory diseases is also recognised 
increasingly. When these comorbidities are present, the 
prognosis is worse; for example, mortality increases in 
those with both chronic obstructive pulmonary disease 
(COPD) and bronchiectasis (hazard ratio, 2.54; 95% CI, 
1.16–5.56).6 As many as 9% of newly referred children 
with chronic cough in Australia have bronchiectasis,8 
and 40% of newly referred adults with difficult asthma 
have bronchiectasis.9 As effective management influences 
prognosis and quality of life,10 a heightened vigilance by 
health professionals is needed to ensure an early dia-
gnosis is made and treatment is optimised.
There is still a paucity of data and clinical trials on bron-
chiectasis, but encouraging trends of better evidence 
have emerged. These include studies related to defining 
CSLD in children,10,11 airway clearance, rehabilitation, 
and use of nebulised and long-term maintenance anti-
biotics to prevent exacerbations. These studies (obtained 
through systematic searches12) formed the basis for our 
updated recommendations. When evidence was lacking, 
Australian and New Zealand experts (the writing group) 
developed the recommendations, which were further 
informed by the voting group using a modified Delphi 
process and the GRADE (grading of recommendations 
assessment, development and evaluation) system.13
Of the 32 recommendations, eight are new (3, 8, 10, 14, 
25, 30–32), seven unaltered (7, 17–18, 22–24, 29) and the 
remaining 17 were amended. We refer readers to the 
Thoracic Society of Australia and New Zealand website 
for the full guidelines (http://www.thoracic.org.au/
professional-information/position-papers-guidelines/
bronchiectasis) including information about our guide-
lines development process, details of the systematic 
searches, evidence for the recommendations, implications 
of the strength of recommendations, suggested antibiotic 
regimens for management and updated references.12
Guidelines on managing chronic suppurative lung disease (CSLD) and bronchiectasis (unrelated to cystic ﬁ brosis [CF]) in 
Australian Indigenous children initiated in 20021 were extended to include Indigenous adults in 20082 and children and adults 
living in urban areas of Australia and New Zealand in 2010.3 Here, we present an updated guideline relevant for all sections of the 
community. The recommendations in this guideline are targeted principally to primary and secondary care, and are not intended 
for individualised specialist care. As with all guidelines, they are not a substitute for sound clinical judgement, particularly when 
investigating and treating such a phenotypically heterogeneous condition as bronchiectasis.4
  Number Recommendation
GRADE 
category
Evidence 
level
  Deﬁ nitions
  1 a. Bronchiectasis is a clinical syndrome in a child or adult with the symptoms and/or signs 
outlined below as well as characteristic radiographic features on chest high-resolution computed 
tomography (c-HRCT).
Symptoms and signs include recurrent wet or productive cough episodes ( 3 per year), each 
lasting for > 4 weeks, with or without other features (for example, exertional dyspnoea, symptoms 
of airway hyperresponsiveness, recurrent chest infections, growth failure, clubbing, hyperinﬂ ation or 
chest wall deformity).
In children, triggers for referral to a specialist include one or more of:
persistent wet cough not responding to 4 weeks of antibiotics;
 3 episodes of chronic (> 4 weeks) wet cough per year responding to antibiotics;
a chest radiograph abnormality persisting > 6 weeks after appropriate therapy.
Strong –
b. Chronic suppurative lung disease is a clinical syndrome in children with the symptoms and/or 
signs outlined above, but who lack a radiographic diagnosis of bronchiectasis.
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Number Recommendation
GRADE 
category
Evidence 
level
Investigations of a patient with CSLD or bronchiectasis
2 a. Patients with symptoms and/or signs suggestive of bronchiectasis require a c-HRCT scan to conﬁ rm the 
diagnosis and to assess the severity and extent of bronchiectasis.
Strong Moderate
b. In children, seek specialist advice before ordering a c-HRCT scan; child-speciﬁ c criteria should be used.
c. In both adults and children, a multidetector CT scan with HRCT reconstruction is the preferred technique to 
diagnose bronchiectasis.
3 Consider a c-HRCT scan in adults with COPD and either  3 exacerbations per year, very severe disease (forced 
expiratory volume in 1 second [FEV1] < 30% predicted or requiring domiciliary oxygen) or whose sputum contains 
organisms atypical for COPD (ie, Aspergillus species, Pseudomonas aeruginosa or non-tuberculous mycobacteria).
Low Low
4 Obtaining further history for speciﬁ c underlying causes may determine subsequent investigation and management. 
This includes history of, or suggestive of:
cystic fibrosis (family history, pancreatitis, chronic gastrointestinal symptoms, male infertility);
underlying immune deficiency or ciliary dyskinesia (recurrent sinusitis, extrapulmonary infections, including 
discharging ears and severe dermatitis, and male infertility);
recurrent aspiration (cough and/or choking with feeds or meals; after bariatric surgery; may be occult);
an inhaled foreign body.
Strong Moderate
5 Perform or refer for baseline investigations. Minimum investigations are:
full blood count and major immunoglobulin classes G, A, M, E;
sweat test in all children and selected adults (see full guidelines12);
culture of airway secretions, including specialised cultures for mycobacteria, particularly non-tuberculous 
mycobacteria in sputum-producing patients;
spirometry and lung volumes (patients aged > 6 years); and serological tests for Aspergillus species.
In selected patients, other investigations should be considered (see full guidelines12).
Strong Moderate
6 Obtain further history to determine markers of severity, impact of illness, comorbidities and modiﬁ able risk factors. 
History should include frequency of exacerbations and hospitalisations, degree of eff ort limitation, exposure to 
tobacco smoke and other pollutants, childhood history, and housing.
Strong Low
Management
7 Aim to optimise general wellbeing, symptom control, lung function and quality of life, and to reduce exacerbation 
frequency and prevent excessive decline in lung function. This may require intensive medical therapy.
Strong High
8 Develop treatment plans for exacerbations for each patient, linking them to primary health care and specialist or 
hospital facilities. When appropriate, this includes individualised and self-initiated management action plans.
Strong Low
9 Base antibiotic selection on lower airway culture results (sputum, bronchoscopy washings [adults and older 
children] or bronchoalveolar lavage [young non-expectorating children]) when available, local antibiotic 
susceptibility patterns, clinical severity and patient tolerance, including allergy (Appendix).
Strong Moderate
10 When P. aeruginosa is ﬁ rst detected, consider discussion with a specialist in this ﬁ eld regarding suitability for 
eradication treatment.
Weak Low
11 In patients not requiring parenteral antibiotics for an acute exacerbation, oral antibiotics are prescribed for at least 
10 days based on available airway microbiology results. Close follow-up to assess treatment response is necessary.
Strong Low
12 Inadequate response should prompt repeat of lower airway cultures and assessment of whether parenteral 
antibiotic therapy and hospitalisation are needed.
Strong Moderate
13 Patients in whom oral antibiotic therapy for an acute exacerbation fails should receive intensive airway clearance 
strategies and parenteral antibiotics based on the latest lower airway culture results. Close follow-up is required.
Strong Moderate
a. In children, this requires supervised treatment for at least 10–14 days.
b. In adults, intravenous antibiotics should be administered for at least 5 days and often need to be followed by oral 
antibiotics. Conversion from intravenous to oral antibiotics depends on appropriate oral alternatives and whether 
eff ective adjunct therapies, such as airway clearance strategies, can be maintained in an ambulatory care setting and 
with ongoing outpatient review.
14 Long-term oral antibiotics should not be prescribed routinely. Macrolides (or other antibiotics) can be considered 
for a therapeutic trial over a limited period (eg, up to 12–24 months) in selected patients (eg, those with frequent 
exacerbations [ 3 exacerbations and/or  2 hospitalisations in the previous 12 months]).
Before commencing macrolide antibiotics:
seek respiratory/infectious diseases specialist advice;
ensure non-tuberculous mycobacteria infection is excluded in patients capable of providing a sputum specimen;
perform electrocardiography in adults for assessment of QT interval corrected for heart rate.
Strong Moderate
15 Long-term nebulised antibiotics should not be prescribed routinely. Consider a therapeutic trial in children and 
adults with frequent exacerbations and/or P. aeruginosa infection.
Strong Moderate
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16 Inhaled and oral corticosteroids should not be prescribed routinely unless there is an established diagnosis of 
coexisting asthma or COPD.
Strong Low*/ 
moderate†
17 Inhaled bronchodilators should not be prescribed routinely but used only on an individual basis. Strong Low
18 Recombinant human deoxyribonuclease is contraindicated in CSLD and bronchiectasis. Strong High
19 Mucoactive agents, including hypertonic saline and mannitol, are currently not recommended for routine use. 
Consider a therapeutic trial in children and adults with frequent exacerbations.
Weak Moderate
20 Airway clearance techniques are recommended and a respiratory physiotherapist’s advice should be sought. 
Individualise airway clearance therapy.
Strong Moderate
21 Adults with bronchiectasis and exercise limitation should receive pulmonary rehabilitation. Strong Moderate
22 Regular physical activity is recommended for children and adults with CSLD or bronchiectasis. Strong Low
23 Assess and optimise nutritional status. Strong Moderate
24 Promote elimination of smoking, including second-hand smoke exposure. Strong High
25 Promote avoidance of environmental airborne pollutants. Strong Low
26 Regularly monitor and manage complications and comorbidities. When present, manage following standard 
guidelines.
Regular review consists of at least an annual review in adults and 6-monthly review in children. A multidisciplinary 
team is preferable, especially at the initial evaluation.
Review includes:
assessment of severity, which includes oximetry and spirometry;
sputum culture (when available) for routine bacterial and annual mycobacterial culture;
management of possible complications and comorbidities, particularly gastro-oesophageal reflux disease or 
aspiration, reactive airway disease or asthma, COPD, otorhinolaryngeal disorders, urinary incontinence, mental 
health and dental disease. Less commonly, patients require assessments for sleep disordered breathing and 
cardiac complications;
checking adherence to therapies and knowledge of disease processes and treatments.
Strong Moderate
27 Although surgery is not indicated normally, assessment by a multidisciplinary team expert in CSLD and 
bronchiectasis care may be required in some circumstances.
Strong Moderate
Public health issues, prevention and appropriate health care delivery
28 Vaccinate according to the National Immunisation Program Schedule. Ensure timely annual inﬂ uenza vaccination 
and that pneumococcal vaccines are administered following national guidelines.
Strong Moderate
29 Coordinated care by health care providers is necessary. If bronchiectasis is suspected, specialist evaluation is 
recommended to conﬁ rm the diagnosis, investigate the aetiology, assess severity and develop a management plan. 
Patients with moderate or severe disease are best managed using a multidisciplinary approach to chronic care 
with individualised case management. Clinical deterioration should prompt early referral to services with CSLD and 
bronchiectasis expertise.
Strong Low
30 Specialist review should be undertaken for patients with moderate disability or progressive lung disease. This 
includes consideration for lung transplantation.
Strong Low
31 Providing health care for Indigenous people in rural and remote regions requires ﬂ exible and adaptive arrangements. 
However, this should not alter the objective of delivering best-practice treatment to this population.
Strong Low
32 Given the high prevalence of CSLD and bronchiectasis in Indigenous Australians, Maori and Paciﬁ c Islander children 
and adults, a high index of suspicion with early diagnostic investigation should be established, as well as best-
practice treatment. Interpreters and local health workers should be available for educating patients about the 
disease and its management.
Strong Moderate
* For oral corticosteroids. † For inhaled corticosteroids.
Number Recommendation
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level
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